INTRODUCTION

Apoptosis research is saving the reputation of chemotherapy
Chemotherapy has a bad reputation with many patients, their relatives and even with a number of physicians who are not active in the field of oncology. The reason for this is perhaps that chemotherapy is considered as a purely toxic principle that is given with the hope that the tumor is more sensitive than the patient. With the recognition that chemotherapeutic drugs induce apoptosis, the whole perception of chemotherapy has changed. We now know that most, if not all, chemotherapeutic drugs do not act directly but induce complex biochemical pathways that ultimately result in apoptosis. Up to now a number of different apoptosis trials such as the bcl-2, bax, bcl-xL system, the CD95 pathway, the p53-system and cytochrome-C release from mitochondria have been described, but we still do not know the exact interconnections between these pathways.
The 6th Workshop of the Cooperative Study Group Cellular Resistance (CSG-CR) entitled 'Apoptosis and Chemotherapy Resistance' was held in October 1997 in Linz, Austria. After intensive discussions five stringently peer-reviewed articles published in this issue of Leukemia have arisen from the contributions of this workshop. The rather long publication time results from the emergence of new data in the literature which in turn compelled authors to new experiments. This group of five papers reflects the heterogeneous conceptions that exist Correspondence: F Gieseler, Christian-Albrechts-Universität, Klinik fü r Allgemeine Innere Medizin, Schwerpunkt Hämatologie/ Onkologie, Schittenhelmstrasse 12, 24105 Kiel, Germany in this active field of research. Every workgroup presents a rationale and a set of experiments that are well thought out and performed. Nevertheless, the conclusions are not necessarily the same and are sometimes even contradictory. For example, with similar experimental settings exploring the effects of anthracyclines in leukemia cells, the group of Friesen et al deduce that the CD95-pathway plays a critical role, whereas the group of Gieseler et al conclude that the inhibition of topoisomerase II is decisive. Obviously, the biochemical scene of apoptosis is a composite network that is affected by a large number of factors. Also, the apoptosis network seems to be differently regulated in cells of lymphatic and myeloid origin, which is precisely described in the papers by Nuessler et al, Stoetzer et al and Andreeff et al.
The elucidation of both the apoptosis defects in tumor cells and the specific effects of chemotherapy upon apoptotic pathways, results in a better comprehension of the therapeutic potentials. There is hope that the combination of apoptosis induction by classical chemotherapy combined with the alteration of the cellular response by 'biological response modifiers' may improve future oncological therapy. 
